EMEA-002975-PIP01-21 - paediatric investigation plan

[18F]CTT1057

Key facts

• Active Substance:
  [18F]CTT1057
• Therapeutic area:
  Oncology
• Decision number:
  P/0258/2021
• PIP number:
  EMEA-002975-PIP01-21
• Pharmaceutical form(s):
  All pharmaceutical forms
• Condition(s) / indication(s):
  Visualisation of prostate-specific membrane antigen in adenocarcinoma of the prostate
• Route(s) of administration:
  All routes of administration
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  09/07/2021

Decision

P/0258/2021: EMA decision of 9 July 2021 on the granting of a product specific waiver for [18F]CTT1057 (EMEA-002975-PIP01-21)

Reference Number: EMA/317695/2021